NCT05159518
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MYC
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: If patients have HER2+ breast cancer, they only qualify for this trial if the cancer also expresses a MYC mutation; Patients with TNBC or ER+ breast cancer are not required to also have a MYC mutation
Exclusions: Patients with uncontrolled central nervous system (CNS) metastases; Patients with prior exposure to a CDK9 inhibitor
https://ClinicalTrials.gov/show/NCT05159518